PE20240222A1 - Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion - Google Patents
Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacionInfo
- Publication number
- PE20240222A1 PE20240222A1 PE2023001504A PE2023001504A PE20240222A1 PE 20240222 A1 PE20240222 A1 PE 20240222A1 PE 2023001504 A PE2023001504 A PE 2023001504A PE 2023001504 A PE2023001504 A PE 2023001504A PE 20240222 A1 PE20240222 A1 PE 20240222A1
- Authority
- PE
- Peru
- Prior art keywords
- indol
- pyrazole
- cyano
- isopropyl
- carboxylic acid
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200166051 | 2020-12-01 | ||
| PCT/KR2021/017842 WO2022119269A1 (ko) | 2020-12-01 | 2021-11-30 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240222A1 true PE20240222A1 (es) | 2024-02-16 |
Family
ID=81854222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001504A PE20240222A1 (es) | 2020-12-01 | 2021-11-30 | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240000751A1 (https=) |
| EP (1) | EP4257123A4 (https=) |
| JP (1) | JP7678106B2 (https=) |
| KR (1) | KR20220077091A (https=) |
| CN (1) | CN116528852A (https=) |
| AR (1) | AR124178A1 (https=) |
| AU (2) | AU2021390901B9 (https=) |
| CA (1) | CA3197405A1 (https=) |
| CL (1) | CL2023001215A1 (https=) |
| CO (1) | CO2023008265A2 (https=) |
| MX (1) | MX2023005459A (https=) |
| PE (1) | PE20240222A1 (https=) |
| TW (3) | TWI896975B (https=) |
| WO (1) | WO2022119269A1 (https=) |
| ZA (1) | ZA202305156B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240242A1 (es) * | 2021-06-15 | 2024-02-16 | Lg Chemical Ltd | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05000862A (es) * | 2002-07-31 | 2005-04-19 | Pharmacia Corp | Forma de dosificacion farmaceutica capaz de mantener un perfil de disolucion estable tras el almacenamiento. |
| DE602006014607D1 (de) * | 2005-01-21 | 2010-07-15 | Teva Pharma | Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung |
| JP5330989B2 (ja) * | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | （アザ）インドール誘導体及びその医薬用途 |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| WO2020109319A1 (en) * | 2018-11-27 | 2020-06-04 | Zaklady Farmaceutyczne Polpharma S.A | Pharmaceutical composition comprising ramipril and indapamide |
| US20240000750A1 (en) * | 2020-11-04 | 2024-01-04 | Lg Chem, Ltd. | Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same |
| PE20230850A1 (es) * | 2020-12-01 | 2023-05-23 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion |
| TWI903066B (zh) * | 2021-04-16 | 2025-11-01 | 南韓商Ｌｇ化學股份有限公司 | 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物 |
-
2021
- 2021-11-30 PE PE2023001504A patent/PE20240222A1/es unknown
- 2021-11-30 CN CN202180078624.3A patent/CN116528852A/zh active Pending
- 2021-11-30 MX MX2023005459A patent/MX2023005459A/es unknown
- 2021-11-30 AR ARP210103303A patent/AR124178A1/es unknown
- 2021-11-30 WO PCT/KR2021/017842 patent/WO2022119269A1/ko not_active Ceased
- 2021-11-30 TW TW112117938A patent/TWI896975B/zh active
- 2021-11-30 TW TW110144682A patent/TWI840721B/zh active
- 2021-11-30 EP EP21900957.8A patent/EP4257123A4/en not_active Withdrawn
- 2021-11-30 JP JP2023533382A patent/JP7678106B2/ja active Active
- 2021-11-30 US US18/255,212 patent/US20240000751A1/en active Pending
- 2021-11-30 CA CA3197405A patent/CA3197405A1/en active Pending
- 2021-11-30 KR KR1020210167928A patent/KR20220077091A/ko active Pending
- 2021-11-30 TW TW114111064A patent/TW202600130A/zh unknown
- 2021-11-30 AU AU2021390901A patent/AU2021390901B9/en active Active
-
2023
- 2023-04-27 CL CL2023001215A patent/CL2023001215A1/es unknown
- 2023-05-10 ZA ZA2023/05156A patent/ZA202305156B/en unknown
- 2023-06-23 CO CONC2023/0008265A patent/CO2023008265A2/es unknown
-
2024
- 2024-10-16 AU AU2024227367A patent/AU2024227367A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI896975B (zh) | 2025-09-11 |
| CL2023001215A1 (es) | 2023-12-15 |
| CA3197405A1 (en) | 2022-06-09 |
| WO2022119269A1 (ko) | 2022-06-09 |
| JP7678106B2 (ja) | 2025-05-15 |
| EP4257123A1 (en) | 2023-10-11 |
| AU2021390901B9 (en) | 2024-11-21 |
| KR20220077091A (ko) | 2022-06-08 |
| AU2024227367A1 (en) | 2024-10-31 |
| JP2023551712A (ja) | 2023-12-12 |
| ZA202305156B (en) | 2024-09-25 |
| AU2021390901A1 (en) | 2023-06-08 |
| TW202600130A (zh) | 2026-01-01 |
| AU2021390901B2 (en) | 2024-11-07 |
| TW202408496A (zh) | 2024-03-01 |
| TWI840721B (zh) | 2024-05-01 |
| AU2021390901A9 (en) | 2024-05-23 |
| US20240000751A1 (en) | 2024-01-04 |
| CN116528852A (zh) | 2023-08-01 |
| EP4257123A4 (en) | 2024-05-08 |
| AR124178A1 (es) | 2023-02-22 |
| CO2023008265A2 (es) | 2023-06-30 |
| TW202228679A (zh) | 2022-08-01 |
| MX2023005459A (es) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| PE20240222A1 (es) | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion | |
| ES2928399T3 (es) | Composición farmacéutica bactericida que comprende ibuprofeno | |
| PE42598A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| MX392901B (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona | |
| JOP20240055A1 (ar) | عقار أولي من مشتقات بيروليدون كمنشط جلوكوكيناز | |
| JOP20240258A1 (ar) | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| US9096585B2 (en) | Antiviral compounds and uses thereof | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| US20170065587A1 (en) | Antiviral axin stablizer | |
| PH12021551035A1 (en) | Pyrazoles as modulators of hemoglobin | |
| US20220354825A1 (en) | Pharmaceutical composition for prevention or treatment of inflammatory diseases comprising naphthoquinone derivative | |
| Marcinkiewicz et al. | Current opinion on the therapeutic capacity of taurine-containing halogen derivatives in infectious and inflammatory diseases | |
| CO2024017734A2 (es) | Compuesto novedoso y composición farmacéutica que comprende la misma como ingrediente activo | |
| ZA202311237B (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| CN114712355B (zh) | Rhps4在制备抑制金黄色葡萄球菌和铜绿假单胞菌药物中的应用 | |
| JP2009078977A (ja) | 心筋の小胞体ストレス抑制剤 | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| PE20230850A1 (es) | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion | |
| ES2332462T3 (es) | Composicion farmaceutica de derivados de piperazina. | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| EP3936132A1 (en) | Azelastine as antiviral treatment | |
| EP1517687B1 (de) | Arzneimittel zur behandlung des "systemic inflammatory response syndrome" | |
| US20220348605A1 (en) | Antimicrobial compounds, compositions, and uses thereof |